Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Baxter gets rights to Chatham’s hemophilia B gene therapeutic AskBio009

Executive Summary

Chatham Therapeutics LLC (the hemophilia-focused affiliate of large-molecule delivery company Asklepios BioPharmaceutical Inc. (AskBio)) has licensed Baxter BioScience (the recombinant and plasma-based proteins division of Baxter International Inc.’s Baxter Healthcare Corp.) exclusive worldwide rights to its Phase I gene therapeutic AskBio009 for hemophilia B, a single-gene disorder caused by deficient gene coding on the X chromosome of the blood clotting Factor IX.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies